Matches in Wikidata for { <http://www.wikidata.org/entity/Q82541477> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q82541477 description "article scientifique publié en 2010" @default.
- Q82541477 description "artículu científicu espublizáu en payares de 2010" @default.
- Q82541477 description "scientific article published on 20 November 2010" @default.
- Q82541477 description "wetenschappelijk artikel" @default.
- Q82541477 description "наукова стаття, опублікована в листопаді 2010" @default.
- Q82541477 name "Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property" @default.
- Q82541477 name "Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property" @default.
- Q82541477 type Item @default.
- Q82541477 label "Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property" @default.
- Q82541477 label "Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property" @default.
- Q82541477 prefLabel "Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property" @default.
- Q82541477 prefLabel "Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property" @default.
- Q82541477 P1433 Q82541477-00807A1C-CCE4-4427-A80D-DEB72CF9E544 @default.
- Q82541477 P1476 Q82541477-C2047C84-8DB1-43C0-9B2A-99B5A9D76F2B @default.
- Q82541477 P2093 Q82541477-5DC7D4A7-DD8B-4267-B839-A271EA02D9D9 @default.
- Q82541477 P2093 Q82541477-85251BC3-05A1-411C-8809-ABA901DC0384 @default.
- Q82541477 P2093 Q82541477-8CCD2340-E249-4FCB-A55F-A29CB3A55519 @default.
- Q82541477 P2093 Q82541477-B12DCD18-E6EA-4EB1-9D06-5F63244FA98C @default.
- Q82541477 P2860 Q82541477-A867C7E1-FD30-4552-BEA4-C6AB1354667A @default.
- Q82541477 P304 Q82541477-62A95EC1-3D6F-4151-9CB3-028A478B7C40 @default.
- Q82541477 P31 Q82541477-5FEF9CF6-D534-42C5-915C-62B147D82C84 @default.
- Q82541477 P356 Q82541477-1413CB08-0201-4FA1-9F30-FF0AC640752B @default.
- Q82541477 P433 Q82541477-E3CA378C-FE53-4B77-8057-718068C9A6E8 @default.
- Q82541477 P478 Q82541477-1E36ADD3-16E4-45BD-AE5A-6148C1341654 @default.
- Q82541477 P577 Q82541477-5BB464E2-581C-46C7-84D4-27C1AEE92788 @default.
- Q82541477 P698 Q82541477-999A92DB-B8A7-4CEC-956A-5E1912ED997D @default.
- Q82541477 P921 Q82541477-F1618344-FC06-4253-BBC0-E50ACC8F8A0E @default.
- Q82541477 P356 J.IJCARD.2010.10.073 @default.
- Q82541477 P698 21095028 @default.
- Q82541477 P1433 Q2357863 @default.
- Q82541477 P1476 "Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property" @default.
- Q82541477 P2093 "Masayoshi Takeuchi" @default.
- Q82541477 P2093 "Sayaka Maeda" @default.
- Q82541477 P2093 "Sho-ichi Yamagishi" @default.
- Q82541477 P2093 "Takanori Matsui" @default.
- Q82541477 P2860 Q46466725 @default.
- Q82541477 P304 "264-266" @default.
- Q82541477 P31 Q13442814 @default.
- Q82541477 P356 "10.1016/J.IJCARD.2010.10.073" @default.
- Q82541477 P433 "2" @default.
- Q82541477 P478 "146" @default.
- Q82541477 P577 "2010-11-20T00:00:00Z" @default.
- Q82541477 P698 "21095028" @default.
- Q82541477 P921 Q357519 @default.